View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 12, 2021updated 12 Jul 2022 11:20am

RedHill to continue Phase II/III trial of Opaganib for Covid-19 

RedHill Biopharma is set to continue the global Phase II/III study of orally administered opaganib (Yeliva, ABC294640) in people hospitalised with severe Covid-19 pneumonia.

RedHill Biopharma is set to continue the global Phase II/III study of orally administered opaganib (Yeliva, ABC294640) in people hospitalised with severe Covid-19 pneumonia.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A novel chemical entity, opaganib is a proprietary, first-in-class sphingosine kinase-2 (SK2) selective inhibitor.

The latest development follows a unanimous recommendation to progress after a fourth independent Data Safety Monitoring Board (DSMB) safety review.

The recommendation is based on analysis of the unblinded safety data gathered from the first 255 subjects who received the treatment for 14 days, expanding the total opaganib safety database to around 380 subjects.

The randomised, double-blind, parallel-arm, placebo-controlled study of opaganib in severe Covid-19 pneumonia patients needing hospitalisation and supplemental oxygen has so far enrolled over 75% of subjects at around 40 recruiting sites.

According to recently reported top-line safety and efficacy data from the non-powered US Phase II trial in 40 subjects with Covid-19 pneumonia, opaganib plus standard-of-care showed superior improvement in lowering oxygen need by end of treatment on day 14.

RedHill Biopharma medical director Mark Levitt said: “With approximately 380 patients in the opaganib safety database following this positive fourth DSMB review, we are building a clear picture of the safety profile of opaganib.

“Moreover, adding together the positive Phase II data, the successful DSMB futility reviews and the outcomes from compassionate use of opaganib, we look forward with optimism to the reporting of top-line data from the Phase II/III study, which will provide the clearest indication to date of opaganib’s promise in treating Covid-19.”

Furthermore, data showed no material safety differences between the opaganib and placebo, indicating opaganib’s growing safety database.

In a separate development, the Chinese Center for Disease Control and Prevention director Gao Fu said that Chinese Covid-19 vaccines do not have greater protection rates.

“It’s now under consideration whether we should use different vaccines from different technical lines for the immunisation process.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena